Table 2 Response after GO treatment

From: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

Early deaths 4/57 (7%)  
Blast clearance at day 15 25/46 (54%)  
Therapeutic failures 36/57 (63.1%)  
ORR after GO 19/57 (33.3%)  
CR 15/57 (26%)  
CRp 4/57 (7%)  
ORR by cytogenetic risk groups
 Intermediate 15/43 (35%) P=0.25
 Poor 3/12 (25%)  
ORR by age (years)   
 Age >60 14/35 (40%) P=0.73
 Age <60 5/22 (22.7%)  
ORR by duration of first remission (months)
 <12 8/32 P=0.16
 >12 11/25  
Pgp function
 CR+CRp 0.10±0.09 P=0.0001
 NR 0.37±0.21  
MRP1 function
 CR+CRp 0.15±0.14 P=0.004
 NR 0.35±0.20  
  1. Abbreviations: CR, complete remission; CRp, complete remission with incomplete platelet recovery; GO, gemtuzumab ozogamicin; ORR, overall response rate (CR+CRp); Pgp, P-glycoprotein.